to microvascular complications, atherosclerosis and thrombosis. Platelet hyperreactivity possibly related to an imbalance in arachidonic acid metabolism may be involved. Aortic rings or renal cortex produced a potent inhibitor of platelet aggregation, identified as prostacyclin (PGI2). Release of PGI 2 by tissues from streptozotocin -diabetic rats (aorta: 0.07 + 0.1 ng/ mg wet weight; renal cortex 0.004 + 0.001 ng/mg wet weight) was significantly depressed when compared with controls (aorta: 0.26 + 0.07 ng/mg wet weight; renal cortex: 0.009 + 0.001ng/mg wet weight). Treatment of diabetic animals with insulin for 8 days restored PGI 2 production to normal. The finding that PGI 2 is depressed in the aorta and in the kidney, tissues which develop angiopathy, and that this is normalised by insulin, suggests that impaired PGI 2 production, perhaps associated with platelet hyperreactivity may play a role in the vascular complications of diabetes.
Patients with diabetes mellitus develop microvascular complications and have an increased susceptibility to atherosclerosis [1] and arterial thrombosis [2] . Disorders of blood coagulation and platelet function are reported to be particularly marked in diabetics with vascular disease [3] . This hypercoagulable state may be related to an imbalance in platelet [4] and vessel wall prostaglandin metabolism. We have previously demonstrated that the release of prostacyclin (PGI2) , a potent inhibitor of platelet aggregation, is significantly depressed in experimental diabetes [5] whilst the platelet production of thromboxane is significantly elevated [6] . In this study two approaches have been used to investigate the possible relevance of abnormal PGI 2 to diabetic vascular disease. First, PGI 2 levels in the kidney, a tissue susceptible to microangiopathy, have been estimated and secondly, the effect of insulin treatment on prostacyclin release by aorta and kidney from diabetic rats has been examined.
Me~o~

Animals
Male rats (Alderley Park strain, 90-120 g body weight) were made diabetic by IV injection of streptozotocin (80 mg/kg) 1-3 months prior to use. Glucosuria was confirmed ('Clinistix') and blood samples (0.5 ml) were taken from the dorsal aorta under ether anaesthesia at sacrifice, for glucose estimation by 'Technicon autoanalyser' [7] . Sex and age-matched rats were used as controls. In experiments to examine the effects of chronic insulin treatment, groups of diabetic rats were given single daily injections of a combination of semilente and ultralente (Wellcome) insulin for a period of eight days.
The animals had been diabetic for 27-30 days when insulin treatment was started. They received 60 U semilente insulin per kg bodyweight and 60 U ultralente insulin per kg on the first day, and 20 U semilente/kg and 80 U ultralente/kg on subsequent days. Physiological (0.154 mol/1) saline was administered to groups of diabetic and non-diabetic controls. All injections were given subcutaneously in the morning (-10 a. m.). Blood samples (25-50 ~1) were taken for glucose estimation from the retro-orbital sinus before treatment and 23 h after each injection, and from the dorsal aorta at sacrifice. In one experiment, blood glucose levels were also estimated 4 h after injection. One animal from each group was sacrificed (by cervical dislocation) at hourly intervals throughout the day.
Prostacyclin Estimation
The abdominal aorta and right kidney were rapidly excised (approximately 2 mins) and immersed in Krebs Henseleit buffer The abdominal aorta from normal rats produced greater amounts of PGI 2 (0.26 + 0.07 ng/mg wet weight) than inferior vena cava (0.055 + 0.003 ng/ mg wet weight) under the same conditions.
The production of PGI 2 by the aorta of diabetic rats (0.07 + 0.01 ng/mg) was significantly depressed (p < 0.02) when compared with that of controls (0.26 + 0.07 ng/mg) (Fig. 1) .
Homogenates of rat renal cortex in vitro generated less PGI 2 (0.009 + 0.001 ng/mg wet weight) than rings of abdominal aorta. As with aortic tissue, renal cortex from diabetic animals also released significantly less PGI 2 (p < 0.01) than normal (Fig. 2) .
Effect of Insulin Treatment a) Aorta." Blood glucose levels in diabetic rats fell during the first two days of insulin treatment and were maintained at low level from days 3 to 8 (Fig. 3) . The mean blood glucose in these animals 24 hours after injection was 111 + 14 mg/100 ml. Blood glucose levels remained high in diabetics treated with saline (298 _+ 4 rag/100 ml) and low in control rats (85 + 2 rag/100 ml).
PGI 2 release from the aorta was depressed (p < 0.001) in diabetic rats treated with saline (Fig. 4) . Insulin treatment significantly increased PGI 2 production (p < 0.05) and there was no difference between values for these animals and controls. The activity of the supernatant in inhibiting platelet aggregation was measured in a double channel aggregometer ('Payton'). The quantity of PGI 2 was estimated from a standard curve obtained in each experiment using chemically defined PGI a (sodium salt), and expressed as ng/mg wet weight of tissue. Results are given as mean _+ SEM. Levels of significance were assessed using the Student t test.
An antiserum was raised in rabbits to 5,6-dihydro PGI 2 as the hapten conjugated to bovine serum albumin [8] . The antiserum (1 !~l) was incubated with platelet rich plasma for 30 s before the addition of either chemically defined PGI z or supernatant. ADP was then added after a further 30 s and aggregation recorded. The platelet inhibiting activity of both PGI 2 and of the supernatant was abolished by antiserum, whereas that of PGE 1 and PGD z was only slightly affected (< 15%).
Results
The incubated aortic rings and renal cortex released a potent inhibitor of platelet aggregation. This inhibitory activity was shown to be due to PGI 2 by (a) loss of effect after boiling for 15 s [9] (b) relaxation of bovine coronary artery [10] and (c) inhibition by a specific antiserum.
b) Renal Cortex:
In this experiment, mean blood glucose levels 24 hours after injection were 163 + 15 and 395 + 11 mg/100 ml in diabetic animals treated with insulin and saline respectively, and 99 + 3 mg/ 100 ml in controls. Renal cortex from diabetic animals treated with saline produced significantly reduced amounts of PGI 2 (p < 0.01) (Fig. 5) . Insulin treatment resulted in increased cortical PGI z production. There was no significant difference between PGI 2 production in insulin treated animals and nondiabetic controls.
Discussion
Platelet abnormalities including increased reactivity [4, 11] , spontaneous aggregation [12] , decreased survival [13] , elevated prostaglandin (PG) [4] and malonyldialdehyde [14] production and fi-thromboglobulin release [15] , are found in diabetes and are particularly marked in patients with vascular complications.
The activation of platelets initiates the sequential conversion, by cyclo-oxygenase, of arachidonic acid to the intermediary PG endoperoxides. Endoperoxides can be converted to TxA 2 [16] or PGE2, PGD 2 and PGF2~ [17] by platelet thromboxane synthetase and PG isomerases respectively, or to PGI2 by endothelial cell prostacyclin synthetase [ 18] . TxA 2 is a potent constrictor of vascular smooth muscle [19] and induces platelet aggregation [20] , whereas PGI2 elicits vasodilation [21] and prevents platelet aggregation or induces disaggregation [22] . A biological balance is therefore maintained between activated platelets and the functional endothelial cell.
We have demonstrated that vascular PGI 2 is decreased and that platelet TxA 2 is elevated in experimental diabetes [5, 6] and in diabetic patients [23] . A deficiency in endothelial cell PGI z production, resulting in an inability to cope with the platelet release of TxA 2 and mitogenic factors [24] could be involved in the vascular complications of diabetes. This is supported by our finding that PGI 2 is depressed in the kidney, a tissue which develops microangiopathy.
High rates of PGI 2 production do not occur in the presence of high blood glucose [5] . Prostacyclin is restored to normal by chronic, but not by acute, insulin administration. The effectiveness of chronic insulin may be explained by the longer duration of treatment or by the greater decrease in blood glucose levels at sacrifice (chronic: 30 + 3 rag/100 ml, acute: 179 + 23 rag/100 ml). At present, we are unable to distinguish between these possibilities. However, if prolonged insulin treatment is necessary, then this suggests that a repair process is occurring and that the depressed PGI 2 in diabetes may be due to endothelial cell loss or damage. Alternatively, if the level of blood glucose is critical then hyperglycaemia or an associated metabolic abnormality of diabetes may be responsible. It has been previously shown that increased glucose concentrations [25] and osmolality [26] decrease PG synthesis.
Studies in diabetic animals have shown that insulin treatment or pancreatic islet transplantation decreases the severity of renal [27] and retinal [28] lesions and diminishes ocular fluorescein leakage [29] . There is also evidence from clinical studies that good metabolic control slows the progression of retinopathy [30] and nephropathy [31] . Furthermore, the development of microangiopathy in normal kid- neys following transplantation into diabetic subjects [32] suggests that metabolic factors play a role in small vessel disease. Evidence for a favourable effect of good control on large vessel disease in the diabetic is lacking, although glucose intolerance is known to be a risk factor for cardiovascular disease [1] . If, as these studies suggest, improvement of the metabolic abnormalities of diabetes prevents, or slows, the progression of vascular disease, then the finding that insulin treatment restores prostacyclin to normal is compatible with the suggestion that impaired vessel wall prostaglandin metabolism could play a role in the evolution of diabetic angiopathy.
